Showing results (21-30 of 83) with videos related to
Sort By:
Pageof 9
BMC Cancer|April 18, 2015
The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathwayCaroline Wilson, Penelope Ottewell, Robert E Coleman, et al.Cancers|August 27, 2021
Transcriptomic Profiling Reveals Novel Candidate Genes and Signalling Programs in Breast Cancer Quiescence and DormancyLewis A Quayle, Amy Spicer, Penelope D Ottewell, et al.Journal of Bone Oncology|January 8, 2026
Doxorubicin induces bone loss and modifies multiple cell populations <i>in vivo</i> - Implications for modelling of bone metastasisVeli Kaan Aydin, Lubaid Saleh, Penelope Dawn Ottewell, et al.Cancer Research|March 26, 2002
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cellsIngunn Holen, Peter I Croucher, Freddie C Hamdy, et al.Journal of Cellular and Molecular Medicine|December 18, 2009
The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cellsHannah K Brown, Penelope D Ottewell, Robert E Coleman, et al.Bone|October 20, 2007
The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancerJulia K L Woodward, Ingunn Holen, Robert E Coleman, et al.Molecular Pain|April 21, 2016
Effects of Src-kinase inhibition in cancer-induced bone painMilena De Felice, Daniel Lambert, Ingunn Holen, et al.Life Sciences|September 14, 2007
Zoledronic acid-induced IPP/ApppI production in vivoHannu Mönkkönen, Penelope D Ottewell, Johanna Kuokkanen, et al.Bone|June 28, 2014
Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasisMarie-Therese Haider, Ingunn Holen, T Neil Dear, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|March 14, 2009
Optimizing the yield and utility of circulating cell-free DNA from plasma and serumXiaoyan Xue, M Dawn Teare, Ingunn Holen, et al.Pageof 9